T. Rowe Price Associates, Inc. filed Amendment No. 4 to its Schedule 13G with the SEC on November 16, 2026, disclosing its beneficial ownership position in Vera Therapeutics Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 2,753,148 shares of Vera Therapeutics Inc. common stock.
- Percent of class: The reported holdings represent 3.8% of the class of common stock, as disclosed in the filing.
- Sole voting power: T. Rowe Price Associates reported sole voting power over 2,746,162 shares.
- Sole dispositive power: The filing reports sole dispositive power over 2,753,148 shares, with no shared voting or dispositive power reported.
- Event date: The date of the event requiring this filing is stated as September 30, 2026.
- Filer type: T. Rowe Price Associates, Inc. is identified as an investment adviser (type "IA") organized in Maryland.
T. Rowe Price Discloses 3.8% Stake in Vera Therapeutics as of September 30, 2026
T. Rowe Price Associates, Inc., a Maryland-incorporated investment adviser headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 4 to Schedule 13G regarding its holdings in Vera Therapeutics Inc. (CUSIP 92337R101). The issuer, Vera Therapeutics Inc., is listed on NASDAQ:VERA and maintains its principal executive offices at 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA, 94005, according to the filing.
According to the filing, T. Rowe Price Associates reported aggregate beneficial ownership of 2,753,148 shares of Vera Therapeutics common stock, equal to 3.8% of the class. Of those shares, the filing states that sole voting power is held over 2,746,162 shares, while sole dispositive power covers the full 2,753,148 shares. No shared voting or shared dispositive power is reported. The filing notes under Item 5 that this represents ownership of 5 percent or less of the class.
The filing was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc., and dated November 16, 2026. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further states that T. Rowe Price Associates "hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
What Was Disclosed
T. Rowe Price Associates, Inc. filed Amendment No. 4 to Schedule 13G on November 16, 2026, reporting beneficial ownership of 2,753,148 shares, or 3.8%, of Vera Therapeutics Inc. common stock as of the September 30, 2026 event date, with no shared voting or dispositive power.





Please wait processing your request...